Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 188 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Children With Chronic Conditions Clear all
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)

NCT01998633
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease, HIGM-1, Leukocyte Adhesion Deficiency, IPEX
Interventions
Hematopoietic Stem Cell Transplant
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Months to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 7, 2026, 3:16 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

NCT02932150
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TAF, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 7, 2026, 3:16 AM EDT
Completed Not applicable Interventional Results available

Intensive Unimanual (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegia

NCT02918890
View directory record Official record
Conditions
Cerebral Palsy, Hemiplegia, Children
Interventions
Constraint-induced Movement Therapy, Hand-arm Bimanual Intensive Therapy
Other
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
6 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 7, 2026, 3:16 AM EDT
Completed Not applicable Interventional

Functional Electrical Stimulation for Hemiplegic Cerebral Palsy

NCT01817179
View directory record Official record
Conditions
Hemiplegic Cerebral Palsy
Interventions
FES neuroprosthesis to dorsiflexors on affected leg
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Sep 7, 2026, 3:16 AM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

NCT02184767
View directory record Official record
Conditions
BiPolar
Interventions
ADASUVE®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Sep 7, 2026, 3:16 AM EDT
Completed No phase listed Observational

Use of Surface Electromyography Biofeedback to Improve Reaching in Children With Cerebral Palsy

NCT00473161
View directory record Official record
Conditions
Cerebral Palsy, Weakness, Hypertonia
Interventions
surface EMG biofeedback
Device
Lead sponsor
University of Southern California
Other
Eligibility
1 Month to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Sep 7, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey

NCT05037305
View directory record Official record
Conditions
Pharmacogenomic Testing
Interventions
Educational video
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
798 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 7, 2026, 3:16 AM EDT
Recruiting Phase 4 Interventional

Oral Iron in Children With Chronic Kidney Disease

NCT03991169
View directory record Official record
Conditions
Chronic Kidney Insufficiency, Chronic Kidney Diseases
Interventions
Ferrous Sulfate
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Year to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 7, 2026, 3:16 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

NCT03832998
View directory record Official record
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 7, 2026, 3:16 AM EDT
Completed Not applicable Interventional Results available

Self-management Intervention for Children With Chronic Medical Complexity: Pilot Feasibility Trial

NCT04470193
View directory record Official record
Conditions
Children With Medical Complexity
Interventions
MyChildCMC app
Other
Lead sponsor
University of Utah
Other
Eligibility
1 Year to 20 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 7, 2026, 3:16 AM EDT
Completed Phase 1Phase 2 Interventional

My Scrivener® - Measuring Effectiveness and Dose Response in Children

NCT00919906
View directory record Official record
Conditions
Asperger's Syndrome, Dyslexia, Cerebral Palsy, Attention Deficit Disorder, ADHD, Traumatic Brain Injury, Stroke
Interventions
My Scrivener(R)
Device
Lead sponsor
Obslap Research LLC
Industry
Eligibility
5 Years to 19 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 27, 2010 · Synced Sep 7, 2026, 3:16 AM EDT
Completed Phase 1 Interventional

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

NCT01164163
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ruxolitinib phosphate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
24
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Sep 7, 2026, 3:16 AM EDT
Completed Not applicable Interventional

Inpatient Consultation for High-Risk Chronically Ill Children Receiving Care in an Enhanced Medical Home

NCT02870387
View directory record Official record
Conditions
Chronic Illnesses
Interventions
Comprehensive Care with Inpatient consultation, Usual Inpatient Care
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 18 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 7, 2026, 3:16 AM EDT
Completed Phase 2 Interventional Results available

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

NCT01830127
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, BI 207127 high dose, Faldaprevir, BI 207127 low dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
La Mesa, California • San Diego, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 7, 2026, 3:16 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Examining the Effect of Eye Gaze Technology on Children With Cortical Visual Impairment

NCT06067607
View directory record Official record
Conditions
Cortical/Cerebral Visual Impairment, Cerebral Palsy
Interventions
eye gaze technology
Other
Lead sponsor
Rockhurst University
Other
Eligibility
2 Years to 10 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 7, 2026, 3:16 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

NCT00628108
View directory record Official record
Conditions
Allergic Rhinitis, Chronic Urticaria
Interventions
Levocetirizine 1.25 mg, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
6 Months to 11 Months
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 7, 2026, 3:16 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

NCT04616326
View directory record Official record
Conditions
Chronic Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
45
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 7, 2026, 3:16 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035
View directory record Official record
Conditions
Chronic Kidney Disease, Proteinuria
Interventions
Finerenone (Kerendia, BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 17 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Palo Alto, California • San Diego, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 7, 2026, 3:16 AM EDT
Not listed Not applicable Interventional

The Effect of Combined Armeospring and CIT on Neuro-motor and Functional Recovery in Children With Unilateral CP

NCT02914925
View directory record Official record
Conditions
Cerebral Palsy, Hemiplegia, Upper Extremity Weakness
Interventions
ArmeoSpring/CIT
Device
Lead sponsor
St Mary's Hospital for Children
Other
Eligibility
7 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Queens, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Sep 7, 2026, 3:16 AM EDT
Recruiting No phase listed Observational

Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders

NCT07493096
View directory record Official record
Conditions
Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD), Neurodevelopmental Disorders and Developmental Abnormalities, Developmental Delay (Disorder), Cerebral Palsy (CP), Cerebral Palsy Hemiparetic Cerebral Palsy Spasticity Gait Disorders, Neurologic Postural Balance Impairment, Cerebral Palsy Infantile, Cerebral Palsy Spastic Hemiplegic, Cerebral Palsy, Dyskinetic, Autism Spectrum Disorder, Autism Spectrum Disorder (ASD, Hypoxic Ischemic Encephalopathy, Hypoxic Ischemic Encephalopathy (HIE), Traumatic Brain Injury (TBI), Sensory Processing Disorder, Chromosomal Abnormalities, Genetic Disorders, Down Syndrome (Trisomy 21), Fragile X Syndrome (FXS), RETT Syndrome With Proven MECP2 Mutation, Williams Syndrome, 22q11.2 Deletion Syndrome, Sensorimotor Integration
Interventions
Not listed
Lead sponsor
Healing Hope International
Other
Eligibility
4 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 7, 2026, 3:16 AM EDT
Completed Not applicable Interventional

Delivered Dietary Intervention for Children With Irritable Bowel Syndrome

NCT01339117
View directory record Official record
Conditions
Irritable Bowel Syndrome, Abdominal Pain
Interventions
Low fermentable substrate diet, High fermentable substrate diet
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 7, 2026, 3:16 AM EDT
Recruiting Not applicable Interventional

Complex Rehabilitation Technology Enabled Physical Activity for Children With Motor Delays Via Telehealth in Natural Environments

NCT07252713
View directory record Official record
Conditions
Cerebral Palsy (CP), Motor Disability, Motor Delay
Interventions
Stander Use
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
1 Year to 6 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 7, 2026, 3:16 AM EDT
Terminated Not applicable Interventional

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

NCT00301860
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, melphalan, methotrexate, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Sep 7, 2026, 3:16 AM EDT
Active, not recruiting Phase 2 Interventional

This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

NCT07723924
View directory record Official record
Conditions
Functional Constipation (FC)
Interventions
plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 7, 2026, 3:16 AM EDT